GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » Pretax Margin %

Phio Pharmaceuticals (Phio Pharmaceuticals) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Phio Pharmaceuticals's Pre-Tax Income for the three months ended in Mar. 2024 was $-2.15 Mil. Phio Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Phio Pharmaceuticals's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Phio Pharmaceuticals's Pretax Margin % or its related term are showing as below:


PHIO's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -155.495
* Ranked among companies with meaningful Pretax Margin % only.

Phio Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Phio Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Pretax Margin % Chart

Phio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42,419.05 - - - -

Phio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Phio Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, Phio Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Pretax Margin % falls into.



Phio Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Phio Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-10.826/0
= %

Phio Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-2.154/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phio Pharmaceuticals  (NAS:PHIO) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Phio Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Phio Pharmaceuticals (Phio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.
Executives
Robert J Bitterman director C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford director UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh director, officer: President and CEO 1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev officer: Chief Business Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman director 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc 10 percent owner 1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco officer: Chief Development Officer C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis officer: Secretary and Controller 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581

Phio Pharmaceuticals (Phio Pharmaceuticals) Headlines

From GuruFocus